Keith Blundy – Non-Executive Chairman
Keith Blundy joined Cizzle as Chairman in July 2015. After completing a PhD at the John Innes Institute and a post doctoral Fulbright scholarship in the US on the regulation of plant gene expression, Keith spent 10 years managing and commercialising agricultural biotechnology programmes before transitioning to healthcare through business development. Keith has a BSc and PhD in genetics and an MBA from the London Business School. He was formerly a director of KuDOS Pharmaceuticals Ltd and Mission Therapeutics and currently is on the board of Cytosystems Ltd and Inivata Ltd. He is a member of Cancer Research UK’s Scientific Executive Board and is CEO of Cancer Research Technology, CRUK’s development and commercialisation company.
Dr Dawn Coverley – Chief Scientific Officer and Founder
Dawn Coverley is a cell biologist with 20 years experience in basic cancer-related research. After a first degree in Genetics (Leicester), and a PhD in biochemistry (Cancer Research UK), she moved to Cambridge University in 1992. Her research exploits experimental systems that reconstitute fundamental process associated with DNA metabolism, including DNA repair and DNA replication, and has generated original research articles published in peer review journals including Nature and Nature Cell Biology. In 2001 she was awarded a senior research fellowship by the Lister Institute of Preventive Medicine and established a new research laboratory at the University of York. She founded Cizzle Biotech Limited in 2005, and raised seed corn funding in 2006. She is currently principal investigator of an academic DNA replication research laboratory at York and Chief Scientific Officer of Cizzle.
Mark Wyatt MBA, Ph.D, BSc (Hons)
Mark re-joined EV in 2010 as an Investment Director on the EV tech team.Prior to re-joining EV, Mark spent two years as Bioscience Ventures Manager at London-based Imperial Innovations, with responsibility for the formation of new, and management of existing, early- stage portfolio companies. His role at Imperial involved the analysis of new technology spin-out opportunities, predominantly in the life sciences area, and working with founding academics and incoming management teams to build valuable investment propositions.
Prior to joining Imperial in 2008, Mark spent five years with EV as Investment Manager and then Investment Director with the EV Tech team based in the North West, and before that, six years at Merlin Biosciences, a venture capital and advisory company dedicated to the life sciences sector. He has particular expertise in the healthcare and clean technology sectors.
Morgan Williams – Head of Commercialisation, Yorkshire Cancer Research (Board Observer)
Morgan Williams is Head of Commercialisation at Yorkshire Cancer Research, the UK’s largest regional medical research charity. His primary role is to help move early-stage innovative cancer technologies which will benefit cancer patients towards a position where they become ripe for further development by the pharma or biotech sectors. Prior to joining the charity in early 2009, Morgan was a partner in a Leeds commercial law firm, and advised YCR and other charities over his 20 plus year legal career. His involvement with Cizzle started back in 2006 when YCR made its initial investment into the company. He was a member of the Association of Medical Research Charities IP Working Group that produced the 2011 report “Benefiting from innovation: intellectual property advice for medical research charities.” He has 2 law degrees but often wishes that he had one in molecular biology instead!
Michael Slade - Financial Controller & Company Secretary
Michael is a Chartered Accountant and a member of the Institute of Indirect Taxation. He heads up a small team within the Finance Department of the University of York, which provides accounting, taxation and company secretarial services to a wide portfolio of small and medium sized companies associated with the University. Additionally, he has responsibility for the University's VAT and corporation tax affairs. He began his career with what is now KPMG and then worked for a number of major companies in the region before joining the University.
Rebecca Chalkley - Research and Development Staff
Rebecca has a degree in Biology from Aberystwyth University and an MPhil in Molecular Genetics from Manchester University. Since 2009 she has worked within a variety of translational-research laboratories which focused on cancer (head and neck, lung, breast and diffuse large B-cell lymphoma). Her background is in molecular genetics, pre-cancer genomics, tissue banking and clinical trials. She joined the Coverley group in April 2016. Rebecca undertakes Cizzle research work including the development and application of Ciz1 splice variant selective molecular tools.
Clare Davies - Administrator
Clare joined the University of York in 2011 and joined Cizzle in early 2013. She provides administration support to Dawn Coverley and Cizzle Biotech Limited.
Cizzle Biotech Limited
Heslington Hall, Heslington, York, North Yorkshire, Y010 5DD
UK company 5249093